Adage Capital Partners
CRBP icon

Adage Capital Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Adage Capital Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-528,937
Closed -$6.24M – 864
2024
Q4 		$6.24M Hold
528,937
– – 0.01% 690
2024
Q3 		$10.9M Buy
528,937
+128,937
+32% +$6.6M 0.02% 591
2024
Q2 		$18.1M Sell
400,000
-15,000
-4% -$631K 0.03% 461
2024
Q1 		$16.3M Buy
+415,000
New +$10.2M 0.03% 504

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Exome Asset Management New York $162M AUM 259.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Adage Capital Partners's CRBP Position: Q1 2025 in Review

Adage Capital Partners sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 528,937 shares — an estimated $6.24M sold.

Adage Capital Partners first reported a position in CRBP in Q1 2024 and held it in 4 quarters. The position peaked at $18.1M in Q2 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Adage Capital Partners reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 528,937 Corbus Pharmaceuticals shares in Q1 2025, an estimated $6.24M.
  • Adage Capital Partners first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Adage Capital Partners's Corbus Pharmaceuticals position peaked at $18.1M in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.